Patients with idiopathic pulmonary fibrosis who were given pirfenidone or nintedanib declined more slowly, researchers in two studies reported. [Category: InterMune Inc|ITMN|NASDAQ, Drugs (Pharmaceuticals), Idiopathic Pulmonary Fibrosis, Boehringer Ingelheim GmbH] http://rss.nytimes.com/c/34625/f/640346/s/3a8f7e59/sc/14/l/0L0Snytimes0N0C20A140C0A50C190Chealth0Cdrugs0Efound0Eto0Eaid0Ebreathing0Ein0Ea0Efatal0Elung0Edisease0Bhtml0Dpartner0Frss0Gemc0Frss/story01.htm
Read More
No comments:
Post a Comment